Eupraxia Pharmaceuticals Files 6-K, Includes Press Release
Ticker: EPRX · Form: 6-K · Filed: Sep 19, 2024 · CIK: 1581178
Sentiment: neutral
Topics: reporting, foreign-private-issuer, press-release
TL;DR
Eupraxia Pharma filed a 6-K with a press release on Sept 19. Check it for updates.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on September 19, 2024, reporting for the month of September 2024. The filing indicates that Eupraxia Pharmaceuticals Inc. is a foreign private issuer and will file annual reports under Form 40-F. The report includes Exhibit 99.1, a press release dated September 19, 2024.
Why It Matters
This filing provides an update on Eupraxia Pharmaceuticals' reporting status and includes a press release, which may contain material information for investors.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves to include a press release and confirm reporting status, without disclosing significant new financial or operational events.
Key Players & Entities
- Eupraxia Pharmaceuticals Inc. (company) — Registrant
- September 19, 2024 (date) — Filing date and press release date
- Form 6-K (document) — Filing type
- Form 40-F (document) — Annual report filing type
- Exhibit 99.1 (document) — Included document
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report for the month of September 2024 and to include Exhibit 99.1, which is a press release dated September 19, 2024.
What type of annual report does Eupraxia Pharmaceuticals Inc. file?
Eupraxia Pharmaceuticals Inc. files its annual reports under cover of Form 40-F.
On what date was this Form 6-K filed?
This Form 6-K was filed on September 19, 2024.
What is the principal executive office address of Eupraxia Pharmaceuticals Inc.?
The principal executive office address is 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4.
What is the telephone number for Eupraxia Pharmaceuticals Inc.?
The telephone number for Eupraxia Pharmaceuticals Inc. is (250) 590-3968.
Filing Stats: 169 words · 1 min read · ~1 pages · Grade level 14.6 · Accepted 2024-09-19 17:23:29
Filing Documents
- form6k.htm (6-K) — 11KB
- ex991.htm (EX-99.1) — 15KB
- logo.jpg (GRAPHIC) — 23KB
- 0001279569-24-001139.txt ( ) — 59KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Eupraxia Pharmaceuticals Inc. Date: September 19, 2024 By: /s/ Bruce Cousins Name: Bruce Cousins Title: President and Chief Financial Officer